Regulatory Approval and Compliance - ZEVASKYN, the first and only autologous cell-based gene therapy for RDEB, was approved by the FDA on April 28, 2025, and is manufactured at a cGMP facility in Cleveland, Ohio[14]. - The FDA regulates biologic products, including gene therapy, under the FDCA and PHSA, requiring extensive testing and approval processes[68]. - The process for marketing a biologic product in the U.S. includes preclinical tests, IND application submission, and approval by an independent IRB[70]. - Human clinical trials are conducted in three phases, with Phase 3 requiring sufficient data to confirm efficacy and safety for approval[83]. - The FDA may impose clinical holds on trials due to safety concerns, which must be resolved before trials can commence[73]. - Manufacturers must comply with cGMP regulations and register their establishments with the FDA, with inspections to ensure compliance[86]. - The BLA submission must include evidence of safety, purity, and potency from clinical trials, along with detailed CMC information[88]. - For gene therapies, selecting patients with applicable genetic defects is crucial for effective treatment, and FDA-approved diagnostic tests may be required[89]. - The FDA generally requires simultaneous approval of diagnostic devices when their safe and effective use depends on a therapeutic product[91]. - Post-approval clinical trials may be required to gather additional safety data after initial product approval[80]. - The FDA may approve a therapeutic product without a companion diagnostic if it treats serious conditions and the benefits outweigh risks[92]. - Each Biologics License Application (BLA) must be accompanied by a substantial user fee, which is adjusted annually by the FDA[93]. - The FDA aims to review 90% of standard BLAs within 10 months and 90% of priority BLAs within 6 months after acceptance for filing[100]. - Orphan drug designation can provide financial incentives, including grant funding opportunities and user-fee waivers, but does not shorten the regulatory review process[101]. - If a product with orphan status receives the first FDA approval for its indication, it is entitled to seven years of exclusivity[102]. - The FDA can expedite BLA reviews through programs like Fast Track, Breakthrough Therapy, and Priority Review, which may allow for rolling reviews[104]. - Post-approval, manufacturers must comply with cGMP requirements and report any deviations affecting product safety and efficacy[107]. - The FDA conducts periodic inspections of manufacturing facilities to ensure compliance with cGMP and other regulatory requirements[109]. - Companies must adhere to strict marketing and promotion regulations, prohibiting off-label promotion of products[110]. - Distribution of prescription biopharmaceutical samples is regulated under the Prescription Drug Marketing Act, with specific reporting requirements[111]. - The Drug Quality and Security Act ("DQSA") imposes obligations on biopharmaceutical sponsors for product tracking, requiring electronic transfer of information and product labeling with identifiers[112]. - Non-compliance with regulatory requirements may lead to product marketing restrictions, withdrawal, or civil/criminal sanctions[113]. - The regulatory approval process for gene therapy products is complex and costly, with no assurance of timely approvals[211]. Financial Aspects and Market Dynamics - The annual cost of care for dystrophic epidermolysis bullosa (DEB) is 465% greater than the average annual healthcare cost, highlighting the financial burden of RDEB management[28]. - The sale of a Priority Review Voucher (PRV) related to ZEVASKYN generated gross proceeds of $155.0 million, completed in June 2025[36]. - The commercialization strategy includes securing broad insurance coverage for ZEVASKYN, with coverage from all Medicaid programs across 50 U.S. states and Puerto Rico[40]. - The company faces significant uncertainty regarding coverage and reimbursement for its products, as third-party payors are increasingly reducing reimbursements for medical products and services[136]. - The U.S. government and state legislatures are implementing cost-containment programs, including price controls and required disclosures, which may affect the company's pricing and reimbursement strategies[136]. - The Affordable Care Act has introduced measures such as increased Medicaid rebates and changes to manufacturer discounts, impacting the profitability of the company's drug products[139]. - Future revenue generation is contingent upon successful commercialization strategies, including pricing, contracting, and reimbursement processes[162]. - The company expects to continue incurring losses and may need to raise additional capital to fund operations in the future[157]. - The exclusivity period for ZEVASKYN may not adequately protect against competition from biosimilars, and regulatory changes could further impact this[176]. - Government reform measures may adversely affect pricing and reimbursement for healthcare products, impacting revenue generation and profitability[195]. - New laws and regulations related to healthcare may limit potential revenue and necessitate revisions to research and development programs[196]. Product Development and Manufacturing - As of March 2026, four qualified treatment centers have been activated to administer ZEVASKYN, with ongoing discussions to expand this network[14]. - In clinical trials, ZEVASKYN demonstrated durable wound healing for up to 12 years, with patients having chronic wounds that had remained open for an average of 6.2 years prior to treatment[27]. - The company has established a cGMP manufacturing facility in Cleveland, Ohio, enhancing supply chain control and reducing production costs for ZEVASKYN[50]. - ZEVASKYN is manufactured as multilayer cellular sheets containing gene-corrected keratinocytes, providing immediate wound coverage and promoting healing[51]. - The AAV vector manufacturing process utilizes a triple plasmid transient transfection method, allowing for scalable production of therapeutic gene sequences[52]. - The company has made significant investments in optimized manufacturing processes, aiming to develop best-in-class cell and gene therapy products[54]. - Manufacturing complexities for ZEVASKYN may lead to production delays, affecting the ability to meet market demand[167]. - A full batch of ZEVASKYN manufactured in August 2025 was rejected due to a false positive sterility assay, delaying the product launch[169]. - The company currently lacks a backup manufacturer for ZEVASKYN, which could lead to production delays if an alternative supplier is needed[172]. - Manufacturing risks include potential production interruptions that could impede the ability to supply ZEVASKYN and other products[177]. Intellectual Property and Competitive Landscape - ZEVASKYN has received multiple designations from the FDA, including Orphan Drug and Breakthrough Therapy, which may provide up to seven years of market exclusivity[35]. - Abeona aims to expand its intellectual property portfolio by aggressively seeking patent rights for various aspects of its gene therapy programs[22]. - The company actively seeks patent protection for various technologies, including AAV capsids and gene therapy methods, to maintain a competitive edge in the market[56]. - The company expects to explore strategies for patent term extensions across all patent portfolios[67]. - The company's commercial success is dependent on protecting its intellectual property rights related to ZEVASKYN; challenges to patents could harm its market position[175]. - Intense competition in the biotechnology and pharmaceutical industries may limit the company's ability to successfully develop and market its products[193]. - Mergers and acquisitions in the biotechnology and pharmaceutical industries may concentrate resources among fewer competitors, increasing competitive pressure[143]. Workforce and Organizational Structure - As of December 31, 2025, the company had 226 full-time employees and maintains good relations with its personnel, having never experienced employment-related work stoppages[150]. - The company has contracts with scientific consultants and research organizations to complement its internal expertise in drug development[150]. - The company is focused on attracting and retaining qualified personnel in research and development and manufacturing operations, competing with numerous pharmaceutical and biotechnology firms[149]. Risks and Challenges - The company faces risks related to third-party suppliers, which could disrupt the manufacturing and supply of ZEVASKYN[171]. - The market acceptance of ZEVASKYN is uncertain and depends on factors such as clinical efficacy and safety profile compared to alternative therapies[160]. - The company may incur substantial product liability expenses due to the use or misuse of its products[155]. - The company faces challenges in establishing and maintaining collaborative relationships necessary for the commercialization of its products[187]. - The complexity of data privacy laws, including HIPAA and GDPR, poses risks for the company, with significant penalties for violations[199][201]. - Trade tensions and tariffs may increase research and development costs and disrupt supply chains, negatively affecting growth prospects[205][206]. - The company may experience delays in product development due to supply chain disruptions caused by macroeconomic conditions[207].

Financial Performance - Abeona reported total revenue of $5.8 million for the year ended December 31, 2025, consisting of $3.4 million in license and other revenues and $2.4 million in net product revenue [3]. - Net income for the year ended December 31, 2025, was $71.2 million, or $1.34 per basic share, compared to a net loss of $(63.7) million in 2024 [8]. - Cash, cash equivalents, and short-term investments totaled $191.4 million as of December 31, 2025 [9]. - Total assets increased to $219.6 million as of December 31, 2025, compared to $108.9 million in 2024 [18]. Research and Development - Research and development (R&D) spending decreased to $26.8 million in 2025 from $34.4 million in 2024, primarily due to the FDA approval of ZEVASKYN [6]. Commercialization and Market Access - The first commercial patient treatment of ZEVASKYN was completed in December 2025, with launch momentum expected to build in the first quarter of 2026 [2]. - Selling, general and administrative (SG&A) expenses increased to $65.0 million in 2025, up $35.1 million from 2024, reflecting the commercial transition following ZEVASKYN's approval [7]. - Abeona expanded patient access to ZEVASKYN by activating The University of Texas Medical Branch as the fourth Qualified Treatment Center [2]. - The company expects average net revenues to normalize as the payer mix expands to include commercially insured patients [4]. - The company anticipates that growing treatment experience will catalyze further demand for ZEVASKYN within the RDEB community [2].

Corporate Transactions - PSQ Holdings, Inc. completed a stock-for-stock transaction to acquire EveryLife, Inc. for 1,071,229 shares of common stock[20]. - The company merged with Colombier Acquisition Corp., resulting in the name change to PSQ Holdings, Inc. on July 19, 2023[21]. - The Credova Merger resulted in the issuance of 2,920,993 shares of Class A common stock to Credova stockholders[22]. - The company plans to monetize its Brands segment and has wound down the Marketplace business as of December 31, 2025[24]. - The company is pursuing a divestiture of the Brands segment, but completion and proceeds may be uncertain and less than anticipated, affecting liquidity[115][116]. Business Segments and Offerings - As of December 31, 2025, PSQ Holdings operates under one reportable segment: Financial Technology, which includes Credova, PSQ Payments, and PSQ Impact[25]. - Credova offers a "Buy Now, Pay Later" solution and covers the full credit spectrum, allowing merchants to access a wider consumer pool[32]. - PSQ Payments provides integrated merchant services for debit, credit, and ACH payments, enhancing transaction efficiency for merchants[32]. - PSQ Impact is designed for political campaigns and nonprofits, offering low-fee fundraising and payment processing solutions[34]. - PSQ Holdings aims to create a fully integrated financial ecosystem that combines payments, credit, and fundraising[30]. Marketing and Growth Strategy - The company emphasizes a marketing strategy focused on merchant adoption through targeted partnerships and community-building initiatives[47]. - The growth strategy includes expanding PSQ Payments merchant adoption and scaling Credova consumer financing while maintaining disciplined underwriting and credit quality[54]. - The company focuses on providing consumers with access to multiple financing options through a single application, enhancing choice and flexibility while managing credit risk[49]. Financial Performance and Risks - The company incurred net losses from continuing operations of $24.9 million and $43.6 million for the years ended December 31, 2025 and 2024, respectively, along with negative cash flows from operations of $19.9 million and $34.1 million for the same periods[74]. - The company may require substantial additional capital to support operations and growth, with future capital requirements depending on revenue growth, credit performance, and regulatory requirements[76]. - The company's liquidity could be adversely affected by reserve, collateral, or prefunding requirements imposed by partners or networks, which may increase rapidly in response to adverse events[79]. - The company experiences seasonal fluctuations in consumer spending, with increased activity typically during the fourth quarter due to holiday shopping[56]. Competition and Market Challenges - The company faces significant competition from various participants, including large payment processors and fintech companies, which could materially affect its business and operating results[101]. - Credova operates in a highly competitive BNPL industry, facing increased regulatory scrutiny and potential challenges in maintaining market share[145][146][147]. - Competitive pressures may lead to reduced transaction volumes and lower margins, adversely affecting the company's financial condition[102]. - Credova faces significant competition from larger companies with diversified products and broader consumer bases, which may hinder its market reach and operational efficiencies[148]. Regulatory and Compliance Issues - The company is subject to various federal and state laws regulating consumer finance, which may impact its operations and compliance requirements[63]. - The consumer finance and BNPL industry is subject to significant state and federal laws, and compliance costs may be substantial[207]. - The company has obtained certain state lending licenses, but failure to comply with applicable laws could adversely affect its business and financial condition[211]. - The evolving regulatory environment may impose additional compliance costs and operational limitations on the company[210]. Technology and Operational Risks - The company relies on third-party providers for cloud-based infrastructure, and any disruption in their operations could negatively impact business and financial results[83]. - The payments processing business relies on relationships with sponsor banks and processing partners, and any disruptions could lead to increased costs and reduced processing capacity[118][119]. - Data security breaches and cyberattacks pose a significant risk to Credova's business, potentially compromising confidential information and damaging consumer trust[172]. - The company's ability to process transactions may be hindered by errors in third-party data or technology, affecting loan application approvals[179]. Financial and Credit Risks - The company emphasizes shorter-duration consumer loans to improve capital turnover and manage credit and interest rate risk[54]. - Credova's financing arrangements are unsecured and carry high financial risk, which could lead to increased defaults and adversely affect its financial condition[160]. - Credova is exposed to consumer bad debts, which may significantly impact its financial performance due to the absence of credit checks on consumers[168]. - Credova's allowance for credit losses is based on complex analyses, and incorrect estimates could result in significant charge-offs, adversely impacting its results[161]. Legal and Liability Risks - The company faces potential civil and criminal penalties for non-compliance with privacy laws, which may lead to substantial costs[186]. - Legal claims regarding intellectual property infringement could require significant resources for litigation and may adversely affect business operations[197]. - The company may face significant liabilities from litigation or regulatory actions, which could harm its reputation and financial position[204]. - The company's insurance coverage does not encompass all potential liabilities, which may affect recovery amounts in case of claims[206].

Financial Performance - The company reported net losses of $219.0 million, $169.0 million, and $180.7 million for the years ended December 31, 2025, 2024, and 2023, respectively, with an accumulated deficit of $899.8 million as of December 31, 2025[553]. - The net loss for 2025 was $219.0 million, compared to a net loss of $169.0 million in 2024, indicating an increase in net loss of $49.9 million[582]. - The company has not generated any revenue from product sales since its inception in 2009 and does not expect significant revenue for several years[591]. - The company has not generated any revenue from product sales and does not expect to do so in the foreseeable future[558]. Cash and Liquidity - The company has cash and cash equivalents of $628.1 million as of December 31, 2025, which is expected to fund operations for at least 12 months[557]. - Cash and cash equivalents decreased by $251.4 million in 2025, following a significant increase of $353.1 million in 2024[593]. - Net cash used in operating activities was $249.7 million in 2025, an increase of $85.0 million from $164.7 million in 2024, primarily due to higher cash payments for clinical program activities[594]. - The company has contractual obligations totaling $20.8 million as of December 31, 2025, with payments due over various periods[603]. - Net cash used in financing activities was $0.1 million in 2025, primarily for finance lease obligations[596]. - In 2024, net cash provided by financing activities was $519.8 million, mainly from net proceeds of $544.1 million from a private placement[597]. Operating Expenses - Total operating expenses for 2025 were $319.7 million, compared to $245.1 million in 2024, representing a $74.5 million increase[582]. - Research and development expenses for 2025 were $240.3 million, an increase of $67.3 million from $173.0 million in 2024[582]. - General and administrative expenses for 2025 were $79.4 million, up from $72.2 million in 2024, reflecting a $7.2 million increase[582]. - The company incurred aggregate charges of $5.3 million for severance and other employee termination benefits during the year ended December 31, 2025[550]. - General and administrative expenses increased by $7.2 million in 2025, totaling $79.4 million compared to $72.2 million in 2024, mainly due to increased personnel-related costs and share-based compensation[588]. Research and Development - The company is conducting a Phase I/II clinical trial for nuzefatide pevedotin, targeting EphA2 in patients with advanced solid tumors, and a Phase II trial for recurrent metastatic pancreatic ductal adenocarcinoma[546]. - The company is developing BT1702, a Bicycle Radioconjugate targeting MT1-MMP, and is currently conducting IND-enabling activities[546]. - The company plans to discontinue the Phase I/II trials for zelenectide pevedotin in certain cancer types and convert the Phase II/III Duravelo-2 trial into a randomized Phase II trial[547]. - Research and development expenses increased by $67.3 million in 2025, totaling $240.3 million compared to $172.9 million in 2024, primarily driven by clinical program expenses for zelenectide pevedotin[585]. - The company incurred approximately $283.4 million in direct external expenses for the development of zelenectide pevedotin and $57.2 million for nuzefatide pevedotin since their candidate nominations[586]. Revenue Recognition - The company recognizes revenue primarily through collaborative arrangements and license agreements, which may include upfront fees, milestone payments, and royalties[613][614]. - Revenue is recognized under ASC 606 when the customer obtains control of promised goods or services, reflecting the expected consideration[615][616]. - The company recognizes revenue from licenses of intellectual property when the license is transferred to the customer and they can benefit from it[620]. - Customer options for additional goods or services are evaluated for material rights, and revenue is recognized only when the option is exercised or expires[621]. - Milestone payments in collaboration agreements are included in the transaction price only if it is probable that they will be achieved, with adjustments made at the end of each reporting period[622]. - Sales-based royalties are recognized when related sales occur or when the performance obligation is satisfied, but no sales-based royalty revenue has been recognized to date[623]. Future Outlook and Strategic Plans - The company plans to reduce annual operating expenses by approximately 50% through a workforce reduction of about 30% and strategic reprioritization of its clinical portfolio[550]. - The company expects expenses and capital requirements to decrease in the near term due to cost-saving initiatives, but may increase substantially if it seeks marketing approval for product candidates[554]. - The company expects research and development expenses to decrease in the near term due to cost-saving initiatives and strategic reprioritization announced in March 2026[566]. - The company plans to continue developing its product candidates and expanding its pipeline, including seeking marketing approvals for successful candidates[602]. - The company expects to finance its cash needs through equity offerings, debt financings, collaborations, and other strategic transactions, which may dilute existing shareholders' ownership[608]. - Global economic conditions, including inflation and high interest rates, may adversely affect the company's operating results and ability to raise capital[609].

Financial Performance - Collaboration revenue increased to $123.7 million in 2025 from $75.6 million in 2024, representing a growth of 63.5%[814] - Total operating expenses rose to $177.9 million in 2025, up from $156.7 million in 2024, an increase of 13.5%[814] - The net loss for 2025 was $38.6 million, a decrease of 47.0% from the net loss of $72.7 million in 2024[814] - Other income increased to $14.5 million in 2025 from $11.0 million in 2024, a growth of 32% primarily due to higher interest income[820] - Interest income for 2025 was $12.9 million, up from $10.6 million in 2024, representing a 20.5% increase[820] - The company recorded an income tax benefit of $1.1 million in 2025, compared to a provision of $2.6 million in 2024[822][823] - Net cash used in operating activities was $22.8 million in 2025, compared to a net cash provided of $42.0 million in 2024[834][836] - Cash used in investing activities was $101.8 million in 2025, primarily due to marketable securities purchases of $376.7 million[837] Research and Development - Research and development expenses reached $141.5 million in 2025, compared to $121.6 million in 2024, reflecting a 16.4% increase[814] - Research and development expenses included non-cash stock-based compensation of $10.9 million in 2025, slightly up from $10.6 million in 2024[817] - Research and development expenses include employee-related costs, external research expenses, and other laboratory-related costs, which are significant components of the company's financials[847] - The company must make significant judgments and estimates in determining accrued expenses related to research and development activities[849] Cash and Liquidity - As of December 31, 2025, the accumulated deficit stood at $477.2 million, with cash and cash equivalents totaling $382.1 million[797] - The company anticipates that existing cash and marketable securities, along with proceeds from the 2026 Offering, will support operations into 2029[797] - As of December 31, 2025, the company had $382.1 million in cash, cash equivalents, restricted cash, and marketable securities[824] - The accumulated deficit as of December 31, 2025, was $477.2 million, indicating ongoing operational losses since inception[825] - The company expects to continue incurring losses and will finance operations through equity offerings, debt financings, or collaborations[840][842] Collaborations and Agreements - Monte Rosa received a $50 million non-refundable upfront payment from Roche in November 2023, with potential preclinical milestones up to $172 million and clinical milestones exceeding $2 billion[802] - The 2024 Novartis Agreement includes a $150 million non-refundable upfront payment and potential milestones up to $2.1 billion[805] - The company received an upfront payment of $50.0 million and milestone payments of $12.0 million from Roche under the Roche Agreement, with additional contingent payments exceeding $2 billion possible[861] - Under the 2024 Novartis Agreement, the company received a $150 million non-refundable upfront payment and is entitled to up to $2.1 billion in development, regulatory, and sales milestones[863] - The 2025 Novartis Agreement includes a $120.0 million non-refundable upfront payment, with potential payments totaling up to $5.4 billion in clinical development, regulatory, and sales milestones[865] - The Roche collaboration will focus on identifying MGDs for cancer and neurological diseases, with Monte Rosa leading preclinical discovery[800] - The company is responsible for costs related to research activities, while Novartis will cover development and commercialization costs under the agreements[865] Operating Expenses - General and administrative expenses increased to $36.4 million in 2025 from $35.2 million in 2024, a rise of 3.4%[819] - Personnel costs rose to $23.0 million in 2025, up from $22.2 million in 2024, reflecting an increase of 3.7%[819] Revenue Recognition - Revenue recognition is primarily based on agreements with Roche and Novartis, following ASC 606 guidelines, recognizing revenue when control of goods or services is obtained[851] - The company evaluates the transaction price for revenue recognition based on the likelihood of achieving milestones and the associated risks[857] - The company utilizes its proprietary AI/ML-enabled QuEEN™ discovery engine for the development of licensed programs under the 2025 Novartis Agreement[864] Commitments and Obligations - The company has contractual commitments for lease agreements totaling $54.1 million, expiring in 2032 and 2027[867] - The company is classified as a smaller reporting company under Rule 12b-2 and is not required to provide detailed market risk disclosures for this reporting period[869]

Financial Performance - Cash and cash equivalents were $628.1 million as of December 31, 2025, down from $879.5 million as of December 31, 2024, primarily due to cash used in operations[5] - Net loss for Q4 2025 was $20.2 million, or $(0.29) per share, compared to a net loss of $51.9 million, or $(0.75) per share, in Q4 2024[8] - The net loss for Q4 2025 was $20.154 million, compared to a net loss of $51.854 million in Q4 2024, reflecting a reduction in losses of approximately 61%[12] - The company reported a net loss per share of $0.29 for Q4 2025, an improvement from a loss of $0.75 per share in Q4 2024[12] - Total operating expenses for Q4 2025 were $72.663 million, slightly higher than $71.371 million in Q4 2024, indicating a year-over-year increase of about 1.8%[12] Research and Development - R&D expenses for Q4 2025 were $51.8 million, compared to $49.8 million in Q4 2024, with annual R&D expenses increasing to $240.3 million from $173.0 million[8] - Research and development expenses for the year ended December 31, 2025, totaled $240.283 million, up from $172.966 million in 2024, marking an increase of about 39%[12] - Bicycle Therapeutics plans to convert the ongoing Duravelo-2 trial to a randomized Phase 2 study and deprioritize the internal development of zelenectide[2] - The Phase 2/3 Duravelo-2 trial demonstrated an overall response rate (ORR) of 65% assessed by physicians and 58% confirmed by blinded independent central review (BICR) at the 27-week cutoff[3] - The company expects to present initial dose selection data from the Duravelo-2 trial at an upcoming scientific conference[3] - The first company-sponsored radioligand clinical trial for BT1702 is expected to initiate in 2027, with additional EphA2 human imaging data anticipated in the first half of 2026[4] - The company is initiating new clinical trials for BT1702, an MT1-MMP targeting BRC, and is progressing with trials for BT5528 and BT7480[10] Collaboration and Revenue - Collaboration revenue increased to $48.0 million for Q4 2025 and $72.6 million for the year, compared to $3.7 million and $35.3 million in the respective periods of 2024[8] - Collaboration revenue for Q4 2025 was $47.955 million, a significant increase from $3.708 million in Q4 2024, representing a growth of approximately 1,292%[12] - Bicycle Therapeutics expects to leverage its agreements with NDA and SpectronRx to support the discovery and development of a portfolio of BRCs[10] Strategic Initiatives - The company anticipates annual operational savings of approximately 50% from a proposed workforce reduction of about 30%[3] - Bicycle Therapeutics is focusing on strategic reprioritization to potentially extend its financial runway and reduce expenditures through a proposed workforce reduction[10] - Bicycle Therapeutics has established a 15-year contract with the UK Nuclear Decommissioning Authority for access to up to 400 tonnes of reprocessed uranium to support its radiopharmaceutical pipeline[3] - The company anticipates multiple regulatory pathways for its product zelenectide pevedotin in mUC, indicating potential for future commercialization[10] Assets - The total assets as of December 31, 2025, were reported at $717.597 million, compared to $686.868 million as of December 31, 2024[14]

Financial Performance - Monte Rosa reported a net loss of $46.1 million for Q4 2025, compared to a net loss of $13.4 million in Q4 2024, and a net loss of $38.6 million for the full year 2025, down from $72.7 million in 2024[18]. - Total operating expenses for the year ended December 31, 2025, were $177.9 million, compared to $156.7 million in 2024, reflecting an increase in research and development costs[29]. - The net loss for the year ended December 31, 2025, was $38.6 million, an improvement from a net loss of $72.7 million in 2024[29]. Revenue and Collaboration - Collaboration revenue for Q4 2025 was $2.8 million, significantly lower than $60.6 million in Q4 2024, while total collaboration revenue for 2025 was $123.7 million, up from $75.6 million in 2024[15]. - Collaboration revenue for the year ended December 31, 2025, was $123.7 million, an increase from $75.6 million in 2024[29]. - The company has a collaboration agreement with Novartis for MRT-6160, with potential milestone payments up to $2.1 billion and shared profits from U.S. commercialization[14]. Expenses - Research and Development (R&D) expenses increased to $42.0 million in Q4 2025 from $38.9 million in Q4 2024, with total R&D expenses for 2025 reaching $141.5 million, compared to $121.6 million in 2024[16]. - General and Administrative (G&A) expenses rose to $10.5 million in Q4 2025 from $8.8 million in Q4 2024, with total G&A expenses for 2025 at $36.4 million, compared to $35.2 million in 2024[17]. Cash and Funding - As of December 31, 2025, the company's cash, cash equivalents, restricted cash, and marketable securities totaled $382.1 million, a decrease of $14.1 million from $396.2 million as of September 30, 2025[19]. - The company closed a public equity offering in January 2026, generating approximately $345.0 million in gross proceeds, with net proceeds expected to be around $323.8 million after expenses[20]. - The company anticipates that its cash and cash equivalents, along with proceeds from the 2026 offering, will be sufficient to fund operations and capital expenditures into 2029[21]. - Monte Rosa raised $345 million through an upsized public offering, strengthening its balance sheet to support operations into 2029[2]. Clinical Development - MRT-8102 demonstrated a 85% reduction in CRP levels after four weeks of administration in subjects with elevated CVD risk, with 94% of participants achieving CRP levels below 2 mg/L[4]. - The company plans to initiate multiple Phase 2 studies of MRT-8102, including in patients with Stage 3/4 chronic kidney disease in H2 2026, gout flare patients in Q4 2026/Q1 2027, and hidradenitis suppurativa patients in H1 2027[12]. - Anticipated readout of the GFORCE-1 study for MRT-8102 in subjects with elevated CVD risk is expected in H2 2026[13]. - The company plans to initiate the MODeFIRe-1 Phase 2 study of MRT-2359 in combination with apalutamide in mCRPC in Q3 2026[22]. - An IND application for a cyclin E1-directed MGD is expected to be submitted in 2026[22]. - MRT-2359 showed a 100% PSA response rate in mCRPC patients with AR mutations, with a 67% overall RECIST disease control rate across 15 evaluable patients[7]. Pipeline Development - The company has developed a leading pipeline of first-in-class and only-in-class molecular glue degraders (MGDs) across various therapeutic areas, with three programs currently in the clinic[23]. - The total assets as of December 31, 2025, were $448.7 million, compared to $438.7 million as of December 31, 2024[27].

Financial Position and Debt - As of December 31, 2025, Telesat's U.S. dollar-denominated debt financing amounts to US$2,145.6 million, with significant exposure to foreign currency fluctuations impacting interest payments and capital expenditures [166]. - Approximately 47.1% of Telesat's revenue and 51.6% of operating expenses were denominated in U.S. dollars for the year ended December 31, 2025 [165]. - Telesat's future revenue is expected to be significantly impacted by the value of the Canadian dollar against the U.S. dollar, which could affect its ability to repay Canadian dollar debt [169]. Capital Investments and Revenue Sources - Over 80% of Telesat's expected capital investments in the Telesat Lightspeed program over the next two years will be in currencies other than Canadian dollars, primarily U.S. dollars and Euros [168]. - Telesat anticipates that a material part of its revenues from the Telesat Lightspeed constellation will come from regions where it currently has limited presence, including Europe, Africa, and Asia [182]. - Telesat's analysis of the total addressable market for the Telesat Lightspeed constellation may be inaccurate, potentially leading to lower-than-expected revenues [186]. Competition and Market Position - Telesat faces strong competition from established players like SpaceX and Amazon, which have greater financial resources and advanced satellite deployment capabilities [188]. - The Telesat Lightspeed constellation may struggle to attract customers due to the operational status of competitors like Eutelsat Group/OneWeb and SpaceX, which have already made significant market inroads [189]. - Telesat lacks in-house satellite launch capabilities, relying on third-party providers, which may hinder its competitive position against companies like SpaceX and Blue Origin that have their own launch vehicles [190]. Regulatory Compliance and Challenges - Regulatory compliance is critical for Telesat, as it must navigate complex authorization processes in multiple countries, including Canada, the U.S., and Brazil, to operate its satellites [192]. - Telesat was granted spectrum authorization for Commercial-Ka bands on December 6, 2024, but is still seeking access to Mil-Ka frequencies, which are not included in that authorization [195]. - Failure to obtain or maintain necessary regulatory authorizations could adversely affect Telesat's ability to offer services and impact its financial condition [209]. Operational Capabilities and Technical Risks - The Telesat Lightspeed constellation is projected to consist of over one hundred satellites, with numerous technological risks and uncertainties that could adversely affect Telesat's operations and financial condition [172]. - The Telesat Lightspeed constellation will require significant operational capabilities to achieve commercial viability, which Telesat must develop effectively [181]. - Telesat's Lightspeed satellites will be launched into a low LEO orbit at approximately 400 km for testing before being raised to an operational orbit at around 1,300 km, with planned orbit phases lasting about six months each [212]. Intellectual Property and Legal Risks - Telesat's success depends on its ability to obtain and maintain intellectual property protection for its technology, which is critical for competitive advantage [227]. - The company may incur significant expenses if it fails to protect its intellectual property rights, which could adversely affect its competitive position and financial condition [233]. - Telesat's ability to enforce its intellectual property rights may be limited due to the high costs and uncertainties associated with litigation [244]. Shareholder and Governance Issues - MHR and PSP Investments have substantial governance rights over Telesat, which may conflict with the interests of other shareholders [247]. - The issuance of additional Class B Variable Voting Shares could dilute the voting power of existing Class B shareholders [252]. - Telesat may raise additional equity capital to fund Telesat Lightspeed, which could result in substantial ownership dilution for existing shareholders [251]. Taxation and Financial Implications - Telesat may be subject to SIFT tax, which could reduce after-tax returns for holders of Telesat Partnership Units [288]. - Changes in Canadian tax laws, including interest expense deduction limitations effective from 2024, may adversely affect Telesat's profitability [298]. - Telesat's tax liabilities could be impacted by changes in the mix of earnings across jurisdictions with varying tax rates [298].

Financial Performance - Net revenues for the three months ended January 31, 2026, increased to $6,710,112, representing a 28.8% growth compared to $5,209,715 in the same period of 2025[12] - Gross profit for the same period rose to $4,367,034, up 27.4% from $3,428,470 year-over-year[12] - Net income for the three months ended January 31, 2026, was $930,723, slightly up from $912,975 in the same period of 2025[12] - The company reported a comprehensive income of $2,042,939 for the three months ended January 31, 2026, compared to a loss of $115,611 in the same period of 2025[12] - Total net income for the three months ended January 31, 2026, was $930,723, compared to $912,975 for the same period in 2025, reflecting a slight increase[76] - Basic and diluted earnings per share remained stable at $0.08 for both January 31, 2026, and January 31, 2025[76] Assets and Liabilities - Total current assets increased to $51,160,535, a rise of 2.3% from $50,006,202 as of October 31, 2025[7] - Total liabilities decreased to $5,436,237, down 15% from $6,378,148 in the previous period[10] - Total assets as of January 31, 2026, were reported at $65,621,579, with total liabilities of $5,436,237[88] - Total liabilities as of January 31, 2026, were $3,784,241, compared to $3,784,241 as of October 31, 2025, indicating a stable liability position[89] Cash Flow - Cash and cash equivalents at the end of the period increased to $30,446,369, compared to $28,682,615 at the beginning of the period[17] - The company experienced a net cash provided by operating activities of $1,476,907, significantly higher than $641,511 in the previous year[17] Research and Development - Research and development expenses rose to $606,102, an increase of 11.6% from $543,126 in the prior year[12] - Research and development expenses for the three months ended January 31, 2026, were $606,102, slightly down from $543,126 in the same period of 2025[88] Revenue Recognition - The company’s revenue recognition follows the five-step process outlined in Topic 606, ensuring compliance with accounting standards[23] - The Engineering Business recognizes revenue based on the percentage of completion method, which is measured by the costs incurred to date against the estimated total costs[34] - The Company recognizes revenue based on the five-step process established by Topic 606, which includes identifying contracts, performance obligations, and recognizing revenue upon satisfaction of obligations[24] - For the Marine Technology Business, revenue from outright sales is recognized upon delivery, while rental revenue is recognized daily during the rental period[24] Business Segments - The company has three business segments: Marine Technology Business, Acoustic Sensors and Materials Business, and Defense Engineering Services Business, each contributing to revenue generation through various contracts[30] - The Marine Technology Business generated net revenues of $3,355,003 for the three months ended January 31, 2026, contributing significantly to total revenues of $6,710,112[88] Expenses - The cost of goods sold for the three-month period ended January 31, 2026, included commission costs of $301,438, up from $245,509 in the same period of 2025, representing a year-over-year increase of 22.7%[41] - Depreciation expense for the three months ended January 31, 2026, was $229,280, compared to $205,646 for the same period in 2025, an increase of 11.43%[49] - Total stock compensation expense for the three months ended January 31, 2026, was $26,989, a decrease from $100,145 in the same period of 2025[80] Inventory and Receivables - The total inventory as of January 31, 2026, was $14,195,378, compared to $13,636,512 on October 31, 2025, reflecting an increase of approximately 4.1%[46] - Unbilled Receivables decreased to $1,906,633 as of January 31, 2026, down from $2,988,779 as of October 31, 2025, a decline of 36.2%[51] - Deferred Revenue, current, was $1,159,868 as of January 31, 2026, compared to $1,722,796 as of October 31, 2025, a decrease of 32.6%[54] Taxation - The effective tax rate for the three months ended January 31, 2026, was 21.6%, compared to 2.3% for the same period in 2025, reflecting changes in tax regulations[96] - The company anticipates an increase in its income tax provision for fiscal year 2027 due to changes in the global intangible low-taxed income provisions under the 2025 Tax Act[96] Other Income - The company recorded total other income of $272,838 for the three months ended January 31, 2026, compared to $272,838 in the same period of 2025, reflecting consistent income generation from non-operating activities[89]

Financial Performance - For Q4 2025, Urban One reported net revenue of approximately $97.8 million, a decrease of 16.5% from Q4 2024[2] - The operating loss for Q4 2025 was approximately $54.0 million, compared to an operating loss of approximately $1.9 million in Q4 2024[2] - Adjusted EBITDA for Q4 2025 was approximately $15.6 million, down from approximately $26.9 million in Q4 2024[2] - The net loss for Q4 2025 was approximately $54.4 million or $(12.24) per share, compared to a net loss of $35.7 million or $(7.81) per share in Q4 2024[2] - For the twelve months ended December 31, 2025, net revenue was $374.4 million, a decrease of approximately 16.7% from $449.7 million in 2024[11] - Adjusted EBITDA for 2025 was $56.7 million, down from $103.5 million in 2024, representing a decline of approximately 45.5%[12] - The company reported a net loss attributable to common stockholders of $146.9 million for 2025, compared to a loss of $105.4 million in 2024, indicating an increase in losses of approximately 39.3%[12] - The total operating expenses for 2025 were $544.492 million, up from $525.259 million in 2024, indicating an increase of about 3.4%[36] - The company experienced an operating loss of $170.121 million for 2025, compared to an operating loss of $75.585 million in 2024, reflecting a worsening of approximately 125%[34] Revenue Breakdown - Revenue from the Radio Broadcasting segment for Q4 2025 was $35.1 million, down from $47.7 million in Q4 2024, a decrease of approximately 26.4%[20] - Revenue from the Reach Media segment increased to $13.8 million in Q4 2025 from $9.6 million in Q4 2024, an increase of approximately 43.8%[20] - Revenue from the Digital segment decreased to $14.7 million in Q4 2025 from $18.3 million in Q4 2024, a decline of approximately 19.6%[20] - Revenue from the Cable Television segment decreased to $34.9 million in Q4 2025 from $42.0 million in Q4 2024, a decrease of approximately 16.8%[20] - Radio advertising revenue decreased by $6.9 million or 15.7% to $37.1 million for the three months ended December 31, 2025, compared to $44.0 million in 2024[21] - Political advertising revenue saw a significant decline of $12.6 million, resulting in $0.8 million for the three months ended December 31, 2025, compared to $13.5 million in 2024[21] Expenses and Impairments - The total operating expenses for Q4 2025 were approximately $151.9 million, compared to $119.0 million in Q4 2024[5] - The company incurred $55.3 million in impairment of goodwill and intangible assets in Q4 2025, compared to $24.2 million in Q4 2024, an increase of approximately 128.5%[12] - Impairment of goodwill and intangible assets was approximately $55.3 million for the three months ended December 31, 2025, compared to $24.2 million in 2024[24] - The impairment of goodwill and intangible assets in 2025 amounted to $191.816 million, significantly higher than the $151.755 million recorded in 2024[36] Cash and Debt Management - Cash and cash equivalents decreased to $26.4 million as of December 31, 2025, from $137.6 million in 2024, a decline of approximately 80.8%[15] - Total long-term debt decreased to $429.7 million in 2025 from $579.1 million in 2024, a reduction of approximately 25.8%[15] - Interest expense for 2025 totaled $38.806 million, compared to $48.571 million in 2024, showing a reduction of about 20.5%[34] - The company recorded a gain on retirement of debt of $44.009 million in 2025, compared to a gain of $23.271 million in 2024, indicating an increase of approximately 89%[34] Strategic Initiatives - Urban One plans to realign segment information and expenses effective January 1, 2025, to better evaluate segment performance[38] - The company emphasizes the importance of broadcast and digital operating income as a measure of its core operating segments' performance[42] - Urban One's strategic focus includes expanding its media presence and enhancing content offerings to better serve its target demographics[41] Operational Highlights - Urban One, Inc. operates 76 independently formatted broadcast stations, including 58 FM or AM stations and 16 HD stations, targeting over 30 million households[41] - The company provides advertisers with a unique delivery mechanism to reach African American and urban audiences through its multi-media operations[41] - Urban One's Adjusted EBITDA is a significant measure used by management to evaluate operating performance, although it is not a measure of financial performance under GAAP[42] Future Outlook - The company experienced a significant decline in cable TV prime delivery, down approximately 20.0% from Q3 2025, but expects a recovery of 40.0% - 50.0% in Q1 2026 due to revised Nielsen methodology[4] - The conference call to discuss the fourth quarter results is scheduled for March 12, 2026, at 10:00 a.m. EDT[39] - A replay of the conference call will be available from March 12, 2026, until March 19, 2026, providing access to stakeholders for further insights[40] Shareholder Information - For the three months ended December 31, 2025, Urban One had 4,444,458 shares of common stock outstanding on a weighted average basis, compared to 4,565,959 shares for the same period in 2024, reflecting a decrease of approximately 2.6%[42]